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Summary
In the last decade, research in transplantmedicine has focused on developing interventions in themanagement
of the deceased organ donor to improve the quality and quantity of transplantable organs. Despite the promise
of interventional donor research, there remain debates about the ethics of this research, specifically regarding
gaining research consent. Here, we examine the concerns and ambiguities around consent for interventional
donor research, which incorporate questions about who should consent for interventional donor research and
what people are being asked to consent for. We highlight the US and UK policy responses to these concerns
and argue that, whereas guidance in this area has done much to clarify these ambiguities, there is little
consideration of the nature, practicalities and context around consent in this area, particularly regarding organ
donors and their families. We review wider studies of consent in critical care research and social science studies
of consent in medical research, to gain a broader view of consent in this area as a relational and contextual
process. We contend a lack of consideration has been given to: what it might mean to consent to interventional
donor research; how families, patients and health professionals might experience providing and seeking this
consent; who is best placed to have these discussions; and the socio-institutional contexts affecting these
processes. Further, empirical research is required to establish an ethical and sensitive model for consent in
interventional donor research, ensuring the principles enshrined in research ethics are met and public trust in
organ donation ismaintained.
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Introduction
Since early experiments with renal transplantation in the
1950s, transplant medicine has focused on improving
outcomes for organ recipients, in terms of their survival and
quality of life. Advances in this area have included
developments in immunosuppression, surgical technique
and critical care therapy [1]. In recent years, research in
transplant medicine has focused on interventions in the
management of the deceased organ donor as a means of
improving the quality of transplantable organs [2]. This
interventional research, usually carried out in critical care
settings, ranged from simple changes to donor
management, such as lung protective mechanical
ventilation, to administering hormone or cardiovascular
treatment measures, such as vasopressin, in order to
improve organ usage, graft survival, and, ultimately,
produce better outcomes for organ recipients [3–5].
Although advances in this field hold the promise of
improving both the quality and quantity of organs for
transplant, the processes involved in undertaking
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interventional donor research have recently come under
scrutiny, particularly regarding the ethics and practicalities
involved in gaining consent for these procedures [6]. This
scrutiny is only likely to increase, given that the range and
complexity of potential future interventions is growing. For
example, pre-clinical laboratory research raises the
prospect of immumodulatory and genetic therapies.
Furthermore, in controlled donation after circulatory death
(DCD), which now accounts for 40% of deceased donation
in the UK, interventions may require research which needs
to be carried out while the donor is still alive [7].
In this paper, we review the ambiguities in consent for
interventional research in deceased organ donors and the
policy context to these concerns, including the UK
recommendations for gaining consent in donor research.
We limit our exploration to deceased organ donation
programs, namely donation after brain death (DBD) and
DCD. By reviewing literature from studies in critical care,
alongside insights provided by the social sciences on
consent for medical research, we critically examine the
current understanding of consent in the context of
interventional donor research, with a focus on the
implications for deceased organ donors and their families.
In so doing, we highlight shortcomings in this area and
argue the need for further insight into the nature and
context of consent in this unique area of research.
Ambiguities around consent in
interventional donor research
Whereas there is consensus about the need to advance the
area of interventional donor research, progress is
understood to be hampered by the ethical and legal
ambiguities it engenders. These particularly relate to
clarifying the issue of consent for this type of research [6, 8].
These matters were brought into sharp focus in 2015
with the publication of a randomised controlled trial into the
effects of therapeutic hypothermia in DBD donors in the
USA [9]. The study reported that authorisation (consent) for
the interventional research was gained on the part of the
deceased, either via documentation by the donor on a state
registry before their death or authorisation via a surrogate
decision-maker (such as next of kin). However, the
Institutional Review Board ruled that recipient consent was
not required due to their view that the intervention was low
risk, in relation to its administration and effect on the donor
organs. Following publication of the study, the US consumer
group, Public Citizen, challenged the ethical status of the
research, particularly with regard to the fact that consent
was not taken from recipients who received kidneys from
the trial. They called for an investigation into the trial and for
sanctioning of the institutions who failed to protect the
human subjects in the research [10].
The study by Niemann et al. and the challenge by a
public group regarding the ethics of this type of research
only represents the tip of the iceberg in highlighting the
ethical ambiguities in relation to interventional donor
research. Previous studies in this vein, conducted in
contexts such as the US, UK, Germany and Spain have taken
different, sometimes conflicting, approaches to consent.
Whereas some studies report seeking and documenting
specific consent for participation for the research from
substitute decision-makers, such as a relative, of the donor
[11–16], and/or recipient [16–18], others did not consent, or
did not report to consent, anyone who might have been
affected by the research [19, 20].
Concerns over the matter of who should consent for
interventional donor research have been highlighted in
various stakeholder commentaries, mostly in the US,
where clinical practice and legal and ethical governance
structures are different from the UK. These commentaries
emphasise the uniqueness of this type of research, which
“straddles boundaries rarely encountered in traditional
clinical trials” referring to the fact that, whereas the
intervention happens in the deceased donor, the study
outcomes are usually measured in relation to transplant
recipients [6].
Interventional donor research involves multiple
stakeholders in relation to consent: both the donor and
recipient, but also the family of the deceased [21, 22]. In the
case of the latter, commentators have drawn attention to the
way in which families may be faced with two difficult related
consent decisions – those of donation and of research – at a
time of great emotional distress. As such, some
commentators have classed them as potentially ‘vulnerable
populations’, arguing that careful consideration also needs
to be given to who is best placed to seek consent from this
group [23, 24]. In relation to recipients of the research
organs, questions of what exactly they are consenting to and
when to consent have been raised. For example, does
consent relate to accepting a research organ or to
participate in the research in terms of following up
outcomes, or both? [1, 6, 8].
These commentaries have drawn attention to the
ambiguities around consent in relation to clarifying who the
research subjects are; what, exactly, patients are being
asked to consent to (in the case of recipients); and how
consent is best, and most ethically, taken. Ultimately, these
issues are tied up with preserving the dignity and rights of
both donors and recipients, as well as fears over the
potential for this type of research, if done badly, to interfere
2 © 2020 TheAuthors.Anaesthesia published by JohnWiley & Sons Ltd on behalf of Association of Anaesthetists
Anaesthesia 2020 Cooper et al. | Examining consent for interventional donor research
in public trust in the organ donation and transplantation
process.
Thepolicy context
In response to these debates, a limited number of
guidelines have been developed which attempt to clarify
the legal and ethical issues around interventional donor
research. For example, in the US context, the National
Academies of Science, Engineering and Medicine
published a 2017 consensus report on the matter [25]. This
outlines the ethical, legal and regulatory issues relevant to
donor intervention research in the US and makes
recommendations in response to these issues. The report
highlights the need for research participants to be
respected by a ‘robust process’ of informed consent and
recommends that:
• Specific research consent should be incorporated into
consent registers for organ donation. If this specific
consent for research does not exist, then in potential
donors who lack capacity (which is almost invariably the
case), a surrogate decision-maker should take their
wishes and values into account when authorising for the
research on their behalf
• Potential organ recipients require a two-stage process
for taking consent:
1 Consent to receive a research organ when first
placed on the transplant waiting list
2 Further consent should be sought when the research
organ is offered to the recipient.
The focus of their recommendations therefore revolves
around the ideal of acquiring generic donor consent at the
time of registering a decision to be an organ donor after
death, and the need to consent transplant recipients if
organ donor intervention research hadoccurred.
In the UK context, the legal and ethical decision-making
in terms of consent in the context of donor research
performed after death rests clearly with relatives, as outlined
in the Human Tissue Act of 2004 [26]. However, the
accompanying guidance to the HTA indicates that consent
for research, even for interventions before the removal of
organs, can be gained generically during the family
discussion at the time of consent for organ donation [27].
This ‘generic consent’ includes a general provision
authorising research use if an organ/tissues retrieved for the
purposes of transplantation are not able to be transplanted.
However, generic consent does not necessarily cover
interventions within the body of the donor before organ
retrieval, which would be regulated instead by the Mental
Capacity Act (2005) if the patient is alive and the
Health Research Authority. Consent therefore becomes
problematic in the UK in the context of interventional donor
research.
Recognising this issue, the now disbanded
independent UK Donation Ethics Committee, developed a
summary of the ‘practical issues’ impeding the development
of transplantation research and its guidance on how to
proceed [21]. It highlighted that obtaining donor (or
surrogate) consent for research was part of good practice
but acknowledged that this “risks placing donor families
under additional stress at a difficult time” (p.863). They went
on to recommend that donor consent forms should be
altered to include a general consent to research being
undertaken and for more detailed discussions to be had
with families in the case of interventional donor research. In
the case of recipients, they advised a similar two-stage
process to the one outlined in the USA: consent at the time
of wait-listing and specific consent at the time of the
allocation of the research organ.
More recently, NHS Blood and Transplant’s (NHSBT)
Research, Innovation and Novel Technologies Advisory
Group have developed a classification of study
methodologies which help determine the requirement for
specific, rather than generic, consent for donor research,
even if not strictly required by the HTACode of Practice [28].
Recognising that thewishes of the donor and their family are
paramount when it comes to adequate consent under the
guiding principles of the HTA, NHSBT guidance requires
that specific consent is obtained from the family for
interventional research in potential donors. To add to the
myriad of potentially applicable professional and legal
advice, the Organ Donation (Deemed Consent) Act 2019
was recently passed in England [29], and an updated
accompanying code of practice is expected shortly. The Act
is similar to legislation implemented in Wales since 2015
[30]. Scotland is in the process of changing the applicable
legislation to an ‘Opt Out’ system as well but will have
specifically different legislation covering intervention in the
potential organ donor [31]. Research is currently excluded
from deemed legislations in all UK jurisdictions but that may
not be enough to prevent confusion.
Despite all the recommendations and guidelines, from
both the US and UK contexts, confusion persists around the
very nature, practicalities and context of consent itself, in
this unique form of research. Our argument is that current
guidelines only lead to further questions about consent for
interventional donor research. These include: howdodonor
families (and recipients) understand, experience and make
decisions about donor research; what does it mean, from
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the perspective of health professionals, to seek consent for
such research; andwho is best suited to take consent in such
situations? To consider the complexities of consent in this
vein, we review the literature on consent in critical care
research as well as social science studies of consent for
medical research.
Contextualising consent in
interventional donor research
There has been little interventional donor research
internationally, and virtually none in the UK. Much of the
evidence that underpins practice in this area has been
extrapolated from expert consensus, and published from
non-randomised, unblinded cohort studies often
undertaken in single centres, or within localised donation
and transplant programs. Those interventional studies that
have been done have usually taken place in a critical care
setting, involving deceased patients (following
determination of death using neurological criteria, ‘brain
death’) who were having continued organ support while
awaiting organ retrieval [25]. The last decade has seen the
rapid development of donation following the re-
introduction of DCD, described earlier. Research within a
DCD context may involve consideration of interventions
whilst the patient is alive, with potentially wide-ranging
adverse effects ranging from physical harms to the donor,
through the loss of the ability to donate, to related
psychosocial harms and family experience at the time of
patient death. Insight into research and guidance on
consent in critical care settings can help us begin to unravel
the complexities that may be involved in practically
undertaking consent for interventional donor research, and
how this form of consent might be experienced by different
agents in the process (donor families, health professional,
specialist nurses in organ donation).
The critical care setting is a unique and complex care
environment, in which prospective research participants are
most often unable to make their own decisions regarding
treatment or research since their lungs are ventilated, they
are unconscious [32] and, in the case of most donor
research, deceased, meaning that research consent is often
given by a substitute decision-maker such as a relative.
Current research guidance for incapacitated patients
stresses that potential harms and benefits to the patient
should be explained to substitute decision-makers, but
formal consent is then sought retrospectively from the
patient on recovery, which is clearly impossible in the
context of donation [33, 34]. Other interventions
undertaken within end of life care (e.g. palliative care
research) may be done using best-interests decision-
making in incapacitated patients, but the benefits are
overwhelmingly centred on the patient in such
circumstances [35]. Research ethics panels have
traditionally been unwilling to countenance invasive and
risky research on incapacitated patients done explicitly for
the benefit of others with little, or zero, potential benefit to
the patient. Whilst the potential for successful organ
donation is widely accepted as a ‘good’ in patients who
have consented to organ donation after their death, there is
no mention of research interventions before or after death
within the organ donor register, so patient opinion is
unknown. At present, then decision-making for
interventional donor research would clearly lie with
substitute decision-makers.
Researchers have shown that gaining research consent
from substitute decision-makers in a critical care
environment is a complicated and problematic process,
whichmay not reflect the needs of patients, their family, staff
or the study itself [36]. There is also indirect evidence that
substitute decision-makers are often overwhelmed by the
consent process, especially at times of stress [37]. Crucially,
critical care researchers have highlighted the importance of
considering who approaches substitute decision-makers
about consent for research on their relative. For example,
studies have found that decisions to provide consent by
substitute decision-makers are influenced by the level of
trust placed in the healthcare professionals caring for their
relative; the perceived experience, skills and personality of
the member of staff approaching them about research; and
how information about the study is explained and discussed
[36, 37]. Others have highlighted the potential for the
approach for consent to disrupt existing relations between
critical care staff and families if not done sensitively [32]. In
addition, resources and timing also play a role. Critical care
researchers have found that greater time given to the
consent conversation can be a predictor of substitute
decision-makers providing consent and of better-reported
experiences of the consent process [36, 38, 39]. As such, the
importance given to the role of those seeking and
discussing consent, and the time and resources they are
given to do this, is crucial in the context of consenting for
research in the critical care setting.
Taking these insights one step further, scholars working
at the intersections of medical sociology, anthropology, and
science and technology studies have studied the processes
and practices underpinning ‘informed consent’ in medical
research, arguing for the need to understand the contexts
shaping consent. These scholars have consistently drawn
attention to the tensions between the procedural ideal of
informed consent (i.e. that people make a rational, qualified
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decision based on the information they are provided with)
and its everyday reality (i.e. how consent is actually done in
clinical settings and how people make decisions around
consent) [40, 41]. The largely qualitative research in this area
has shown that potential participants often do not
understand, use or even look at the written information
provided to them when making decisions about consent
[40, 42–44]. Instead, decisions about participating in
medical research are linked to broader social and moral
reasoning [42]; personal concerns and experiences [40, 44,
45]; perceptions about medical research; and trust in the
institutions conducting thework [43, 46].
Such issues are likely to be present, if not more
prominent, in the context of families being asked to consent
to interventional donation research on their relative’s behalf
so soon after being asked to consent for organ donation.
Substitute decision-makers may struggle to understand the
focus and structure of decision-making for incompetent
patients, and their decisions are likely to encompass wider
considerations than the wishes of the deceased, even if
these are known. In the case of potential recipients of
research organs, the desire to have a transplant may
overwhelm all other information provided to them about
potential risks of such organs.
Like the critical care findings discussed above, social
science research has also evidenced the important role
played by those seeking and taking consent for medical
research. Studies have found that the person taking consent
is key to decision-making, including in their ability to
‘translate’ information about the research to patients/
families [43]. Similarly, the practices of those taking consent
are shaped by the demands and perceived characteristics
of the people they seek to consent [47, 48]. In this way,
consent should be considered as a highly relational, rather
than individual, act which is affected by the interactions and
meanings created between those taking and those
providing consent.
These insights are crucial, in particular, for
understanding potential issues around consent in the
context of substitute decision-makers being approached
about interventional donor research. In the UK context,
Specialist Nurses in Organ Donation (SNODs) currently
approach relatives for organ donation consent (family
agreement if the patient is already a registered donor),
followingwhich they ask about research in general or for the
use of retrieved but subsequently not transplanted organs
for research. Only if there is a study requiring specific
consent would the specialist nurse explain to the substitute
decision-maker the research methodology, envisaged
benefits and risks. The expertise and training of SNODs is
directed toward gaining consent for organ donation and
generic research, but not for specific interventional research
methodologies.
This leads to the question of how and by whom consent
should be sought in the context of interventional donor
research and what consequences this may have on the
donation process as a whole. The length of the donation
process can be a reason why families decline or withdraw
their agreement to donate [49]; If SNODs take additional
research consent, this could detract from their management
of the donation itself. This could have potential implications
for the duration of the donation process, family consent and
an increased potential for additional distress on the part of
the family.
Conclusion
What is clear from this examination is that the ethical and
practical ‘problem’ of consent for interventional research in
deceased organ donors is far from resolved.
Commentators, policies and guidance have, thus far, largely
focused on the following ambiguities in terms of donation
research: who should provide consent for this type of
research (donors, who are the research subjects, and their
substitute decision-makers; recipients of the research
organs); what is actually being consented for (in the case of
recipients); and how this consent should be procedurally
carried out. Whilst the production of guidance is obviously
important, our argument is that these have taken the notion
of consent itself for granted, in that a lack of consideration
has been given to the very nature of what it might mean to
consent to this type of research (interventions in the body of
the donor before and after death which has an effect on the
donated organ/s); how families, patients and health
professionals might experience providing and seeking this
kind of consent; who is best placed to have these
discussions; and the social and institutional contexts which
will affect these experiences andprocesses.
Insights into research on consent in critical care settings
and broader social science studies on consent for medical
research shows that consent needs to be considered as a
highly relational process, which is shaped and underpinned
by socio-institutional contexts, such as resourcing, issues of
trust and wider understanding of research. In the context of
consent for interventional donor research, understanding
consent in this way, as a situated, relational process (rather
than the traditional model of informed consent as onewhich
is about information and choice) is vital if developments are
to bemade in interventional donor research.
If we fail to fully explore and grasp the issue of consent
for interventional donor research, the implications may be
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serious. These could range from prolongation of the
research process to the extreme of loss of public trust in
medical research generally and organ donation specifically,
with potential consequences for donor rates. The UK’s
history of such loss of trust, following the Alder Hey organ
retention scandal in particular, makes this a possibility that
needs to be taken seriously. We argue that it is therefore
vital that empirical research is done to look at the processes,
practices and experiences of consent in this form of
research. Doing so could lead to an effective, ethical and
sensitive model for consent in interventional donor
research, greater transparency and acceptability in the
consent process, and, ultimately, ensuring that the
principles enshrined in research ethics are met and public
trust in organ donation ismaintained.
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